Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier

Journal of Nuclear Medicine

Volumn 54, Issue 8, 2013, Pages 1181-1187

  Bauer, Martin ^a   Karch, Rudolf ^a   Zeitlinger, Markus ^a   Stanek, Johann ^a,b   Philippe, Cécile ^a   Wadsak, Wolfgang ^a   Mitterhauser, Markus ^a   Jäger, Walter ^c   Haslacher, Helmuth ^a   Müller, Markus ^a   Langer, Oliver ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b AIT AUSTRIAN INSTITUTE OF TECHNOLOGY   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

11C elacridar; 11C tariquidar; Blood brain barrier; Breast cancer resistance protein; P glycoprotein

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARBON 11; ELACRIDAR; MULTIDRUG RESISTANCE PROTEIN; TARIQUIDAR; TRACER; VERAPAMIL; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ACRIDINE DERIVATIVE; CARBON; DIAGNOSTIC AGENT; QUINOLINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE; TUMOR PROTEIN;

ADULT; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN REGION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; DRUG UPTAKE; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; MALE; MUSCLE HYPOTONIA; NORMAL HUMAN; ORTHOSTATIC HYPOTONIA; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOACTIVITY; RANDOMIZED CONTROLLED TRIAL; SIGNAL DETECTION; 11C-ELACRIDAR; 11C-TARIQUIDAR; CONTROLLED CLINICAL TRIAL; METABOLISM; PROTEIN BINDING; SCINTISCANNING;

11C-ELACRIDAR; 11C-TARIQUIDAR; BLOOD-BRAIN BARRIER; BREAST CANCER RESISTANCE PROTEIN; P-GLYCOPROTEIN;

ACRIDINES; ADULT; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD-BRAIN BARRIER; CARBON RADIOISOTOPES; HUMANS; MALE; NEOPLASM PROTEINS; P-GLYCOPROTEIN; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; QUINOLINES; TETRAHYDROISOQUINOLINES;

EID: 84881456396     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.118232     Document Type: Article

References (30)

1. Agarwal S, Hartz AM, Elmquist WF, Bauer B. Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des. 2011;17:2793-2802.
2. Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol Exp Ther. 2010;333:788-796.
3. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219-234.
4. Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol. 1999;128:403-411.
5. Kannan P, John C, Zoghbi SS, et al. Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther. 2009;86:368-377.
6. 11C] GF120918 by PET in mice. Mol Imaging Biol. 2011;13:152-160.
7. 11C]XR9576 to assess the function of drug efflux transporters using PET. Ann Nucl Med. 2010;24:403-412.
8. 11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. J Med Chem. 2009;52:6073-6082.
9. 11C]tariquidar, a positron emission tomography radiotracer based on a thirdgeneration P-glycoprotein inhibitor. Bioorg Med Chem. 2010;18:5489-5497.
10. Bankstahl JP, Bankstahl M, Römermann K, et al. Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal PET and in-vitro study. Drug Metab Dispos. 2013;41: 754-762.
11. Kannan P, Telu S, Shukla S, et al. The "specific" P-glycoprotein inhibitor tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci. 2011;2:82-89.
12. 11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer. Eur J Nucl Med Mol Imaging. 2012;39:149-159.
13. 11C]substrate scans in rats. Nucl Med Biol. June 15, 2013 [Epub ahead of print].
14. 11C]verapamil. Epilepsia. 2007;48:1774-1784.
15. Wang SW, Monagle J, McNulty C, Putnam D, Chen H. Determination of P-glycoprotein inhibition by excipients and their combinations using an integrated high-throughput process. J Pharm Sci. 2004;93:2755-2767.
16. Wanek T, Kuntner C, Bankstahl JP, et al. A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32:2002-2011.
17. 11C-verapamil and PET. J Nucl Med. 2009;50:1954-1961.
18. 11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data. Clin Pharmacol Ther. 2012;91:227-233.
19. Hammers A, Allom R, Koepp MJ, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19:224-247.
20. Bankstahl JP, Bankstahl M, Kuntner C, et al. A novel PET imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the bloodbrain barrier. J Neurosci. 2011;31:8803-8811.
21. Akaike H. An information criterion (AIC). Math Sci. 1976;14:5-9.
22. Hui L, DelMonte T, Ranade K. Genotyping using the TaqMan assay. Curr Protoc Hum Genet. 2008;chapter 2:unit 2.10.
23. Sunder-Plassmann R, Rieger S, Endler G, Brunner M, Müller M, Mannhalter C. Simultaneous analysis of MDR1 C3435T, G2677T/A, and C1236T genotypes by multiplexed mutagenically separated PCR. Clin Chem Lab Med. 2005;43:192-194.
24. Syvänen S, Blomquist G, Sprycha M, et al. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. Neuroimage. 2006;32:1134-1141.
25. 11C]verapamil and PET. J Cereb Blood Flow Metab. 2007;27:424-433.
26. Kannan P, Brimacombe KR, Kreisl WC, et al. Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET. Proc Natl Acad Sci USA. 2011;108:2593-2598.
27. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther. 2006;112:457-473.
28. Uchida Y, Ohtsuki S, Katsukura Y, et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem. 2011;117:333-345.
29. Eckelman WC, Mathis CA. Targeting proteins in vivo: in vitro guidelines. Nucl Med Biol. 2006;33:161-164.
30. Pardridge WM. Blood-brain barrier biology and methodology. J Neurovirol. 1999;5:556-569.